trending Market Intelligence /marketintelligence/en/news-insights/trending/YdRzKcFa_TWxXQlH9iPCZA2 content esgSubNav
In This List

Amicus Therapeutics raises $201M via underwritten common stock offering

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Amicus Therapeutics raises $201M via underwritten common stock offering

Amicus Therapeutics Inc. raised $201 million from an underwritten offering of common shares.

The Cranbury, N.J.-based company issued 18,720,930 shares at $10.75 apiece, which included the purchase of additional shares by underwriters.

Amicus Therapeutics plans to use the proceeds for the development of its expanded gene therapy pipeline and manufacturing capabilities for Pompe biologic AT-GAA and gene therapy product candidates.

The proceeds will also be used to complete the design and construction of the Amicus Process Science and Gene Therapy Manufacturing facility as well for general corporate and product development purposes.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC acted as joint book-running managers for the offering.